Abstract
Cardiovascular diseases remain leading cause of high mortality in diabetes patients. The article is focused on the influence of diabetes on cardiovascular risks. The prevalence presented, as the significance of the main and additional risk factors of cardiovascular diseases in the development of macrovascular complications in diabetes. In the context of influence on cardiovascular risks, modern glucose lowering drugs are considered, the safety and efficacy properties. Advantages of dapagliflozin underscored, the novel oral drug of new generation, with safe and prominent antidiabetic effect and ability to correct the main factors of cardiovascular risk (obesity, hypertension).
Highlights
Cardiovascular diseases remain leading cause of high mortality in diabetes patients
The article is focused on the influence of diabetes on cardiovascular risks
Advantages of dapagliflozin underscored, the novel oral drug of new generation, with safe and prominent antidiabetic effect and ability to correct the main factors of cardiovascular risk
Summary
Cardiovascular diseases remain leading cause of high mortality in diabetes patients. The article is focused on the influence of diabetes on cardiovascular risks. В многоцентровое, рандомизированное, двойное слепое, плацебо-контролируемое исследование SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus — Thrombolysis in Myocardial Infarction 53) [31], посвященное изучению влияния ингибитора ДПП-4 саксаглиптина на сердечно-сосудистые исходы приняли участие ~16500 пациентов с СД-2 в возрасте ≥40 лет с наличием ССЗ в анамнезе (n=12929) и/или наличием нескольких ФР их развития (n=3533).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
